The Gujarat-based generic drug manufacturer Cadila Pharmaceuticals is reportedly exploring possibility of setting up a manufacturing facility in Bahrain. “We are scouting for partners with strong local presence and credentials in the industry or allied activities,” Cadila Chairman and Managing Director Dr. Rajiv Modi told the newspaper.
Cadila Pharmaceuticals, one of the largest privately held pharmaceutical companies in India, is exploring partnerships for a manufacturing facility in Bahrain, the company’s chairman and managing director Dr Rajiv Modi told the GDN in an exclusive interview.
Decision to set up new drug testing laboratories and strengthening the 31 existing State laboratories is a noteworthy step which will provide assistance to the States’ Drug Regulatory and Food Regulatory Systems says Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals.
Modi continues to focus on producing innovative drugs at affordable prices
The company that started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation has come a long way: it has three innovative medicines to its credit – Polycap (for prevention and treatment of cardiovascular diseases), Risorine (for treatment of tuberculosis) and the recently introduced Mycidac-C, the world’s first active immuno therapy in lung cancer.
Dr Rajiv Modi, CMD, Cadila Pharmaceuticals in an interview with Ananya Sen discusses Cadila’s innovation Mycidiac-C and their new research partnership.
AHMEDABAD: Cadila Pharmaceuticals and UK-based antibiotics discovery major, Helperby Therapeutics have signed a joint agreement on Antibiotic Drug Resistance Research & Development.
The tie-up, formalised during British Prime Minister David Cameron’s one-day visit to India on Thursday, will focus on the discovery of patented ‘resistance breaker’ compounds, the Ahmedabad-based Cadila said in a release on Thursday.
Ahmedabad-based privately held pharma major Cadila Pharmaceuticals Limited and UK based antibiotics discovery major Helperby Therapeutics have signed a joint agreement on antibiotic drug resistance research & development.